Abstract CT517: Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2- advanced breast cancer (aBC): combined biomarker analyses from a Phase 1/2 study in postmenopausal women and a Phase 1 study in postmenopausal Japanese women
Year: 2022
Type: conference-abstract
Source: Cancer Research
Authors: Hiroji Iwata, Aditya Bardia, Simon Lord, Hannah M. Linden, Mario Campone, Kenji Tamura, Kan Yonemori, Toru Mukohara, Cécile Combeau, Nils Ternes, Dimitri Carene, Jeff Ming, Joon Sang Lee, Marina Celanovic, Anne-Laure Bauchet, Monsif Bouaboula, Tomoyuki Tanaka, Yumiko Kawabata, Sarat Chandarlapaty
Institutions: Aichi Cancer Center Hospital, Harvard University, Massachusetts General Hospital, University of Oxford, Seattle Cancer Care Alliance, University of Washington Medical Center, Institut de Cancérologie de l'Ouest, Shimane University Hospital, National Cancer Centre Japan, National Cancer Center Hospital East, Sanofi (France), Sanofi (United States), Sanofi (Japan), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4282977480